Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

University of Malaya30 enrolled

Overview

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE). Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Study Type

INTERVENTIONAL

Enrollment

Conditions

Age Related Macular Degeneration

Interventions

Intravitreal RanibizumabDRUG

Intravitreal bevacizumabDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: • Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease Exclusion Criteria: * History of previous systemic or ocular Anti-VEGF therapy * History of previous intravitreal injection with any drug * Intraocular pressure ≥ 22 * Glaucoma * History or presence of thromboembolic events * Un-controlled blood pressure * Blood donation during the previous 3 weeks * Relevant media opacity of the lens

Locations (1)

University of Malaya Medical Center

Kuala Lumpur, Kuala Lumpur, Malaysia

RECRUITING

Central Contacts

Mohammadreza Peyman, MD

CONTACT

0060173387260 drmpeyman@yahoo.com

Visvaraja Subrayan, Prof

CONTACT

d.visva@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.